Maraviroc Versus Etravirine In Combination With Antiretroviral Therapy In Drug Experienced HIV And Hepatitis Co-Infected Patients

• Status: Withdrawn
• Trial end date: 2010-02-01

Summary

Confirm the safety of maraviroc when used as a component of combination antiretroviral therapy in HIV and Hepatitis co-infected patients.

• Phase: Phase 4

Details

• Lead Sponsor: ViiV Healthcare
• Collaborator: Pfizer
• Treatments: Darunavir; Etravirine; Maraviroc; Raltegravir Potassium; Ritonavir